BRPI0413922B8 - xantinas de 8-heteroarila substituída - Google Patents

xantinas de 8-heteroarila substituída

Info

Publication number
BRPI0413922B8
BRPI0413922B8 BRPI0413922A BRPI0413922A BRPI0413922B8 BR PI0413922 B8 BRPI0413922 B8 BR PI0413922B8 BR PI0413922 A BRPI0413922 A BR PI0413922A BR PI0413922 A BRPI0413922 A BR PI0413922A BR PI0413922 B8 BRPI0413922 B8 BR PI0413922B8
Authority
BR
Brazil
Prior art keywords
xanthines
substituted heteroaryl
compositions
compounds
ars
Prior art date
Application number
BRPI0413922A
Other languages
English (en)
Inventor
Wang Guoquan
M Rieger Jayson
D Thompson Robert
Original Assignee
Adenosine Therapeutics Llc
Clinical Data Inc
Dogwood Pharmaceuticals Inc
Forest Laboratories Holdings Ltd
Pgx Health Llc
Trovis Pharmaceuticals Holdings Inc
Trovis Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adenosine Therapeutics Llc, Clinical Data Inc, Dogwood Pharmaceuticals Inc, Forest Laboratories Holdings Ltd, Pgx Health Llc, Trovis Pharmaceuticals Holdings Inc, Trovis Pharmaceuticals Llc filed Critical Adenosine Therapeutics Llc
Publication of BRPI0413922A publication Critical patent/BRPI0413922A/pt
Publication of BRPI0413922B1 publication Critical patent/BRPI0413922B1/pt
Publication of BRPI0413922B8 publication Critical patent/BRPI0413922B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

8-heteroarila xantinas substituída. a presente invenção fornece compostos e composições farmacêuticas que são antagonistas seletivos de receptores de adenosina a2b (ars). estes compostos e composições são úteis como agentes farmacêuticos.
BRPI0413922A 2003-08-25 2004-08-20 xantinas de 8-heteroarila substituída BRPI0413922B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49787503P 2003-08-25 2003-08-25
PCT/US2004/027133 WO2005021548A2 (en) 2003-08-25 2004-08-20 Substituted 8-heteroaryl xanthines

Publications (3)

Publication Number Publication Date
BRPI0413922A BRPI0413922A (pt) 2006-10-24
BRPI0413922B1 BRPI0413922B1 (pt) 2018-08-28
BRPI0413922B8 true BRPI0413922B8 (pt) 2021-05-25

Family

ID=34272616

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413922A BRPI0413922B8 (pt) 2003-08-25 2004-08-20 xantinas de 8-heteroarila substituída

Country Status (20)

Country Link
US (3) US7342006B2 (pt)
EP (2) EP2295434B1 (pt)
JP (1) JP4769721B2 (pt)
KR (1) KR101222364B1 (pt)
CN (2) CN101851238B (pt)
AR (1) AR045499A1 (pt)
AU (1) AU2004268964B2 (pt)
BR (1) BRPI0413922B8 (pt)
CA (1) CA2536553C (pt)
DK (2) DK1658291T3 (pt)
ES (2) ES2440467T3 (pt)
HK (2) HK1096397A1 (pt)
IL (1) IL173723A (pt)
NZ (1) NZ545715A (pt)
PL (1) PL1658291T3 (pt)
PT (1) PT1658291E (pt)
RU (1) RU2357969C2 (pt)
TW (1) TWI362390B (pt)
WO (1) WO2005021548A2 (pt)
ZA (1) ZA200602333B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2460911C (en) * 2001-10-01 2011-08-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
CA2443023A1 (en) * 2002-02-01 2003-08-07 King Pharmaceuticals Research And Development, Inc. 8-heteroaryl xanthine adenosine a2b receptor antagonists
EP2295434B1 (en) * 2003-08-25 2015-09-30 Dogwood Pharmaceuticals, Inc. Substituted 8-heteroaryl xanthines
US7605143B2 (en) * 2004-08-02 2009-10-20 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity
WO2006034279A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
TW200626155A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CN101084207A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
AU2005329423A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
AR051095A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso comoinhibidores de la estearoil-coa desaturasa
CN101083982A (zh) 2004-09-20 2007-12-05 泽农医药公司 用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物
BRPI0515478A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seu uso como mediadores de estearoil-coa-desaturase
TW200626154A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
WO2006091897A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
WO2006091936A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7618962B2 (en) * 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
CA2612344A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
US7812025B2 (en) 2005-08-12 2010-10-12 Takeda Pharmaceutical Company Limited Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
US20070059740A1 (en) * 2005-08-26 2007-03-15 Linden Joel M Method of targeting a2b adenosine receptor antagonist therapy
US7566401B2 (en) * 2005-10-03 2009-07-28 Kelm Mark A Process for separating and isolating xanthines, individual polar protic monomers, and polar protic oligomers
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
GB0606774D0 (en) * 2006-04-03 2006-05-10 Novartis Ag Organic compounds
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
UA105164C2 (en) 2006-06-16 2014-04-25 Догвуд Фармасьютикалз, Инк Substituted 8-[6-amino-3-pyridyl]xanthines
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US8193200B2 (en) * 2007-01-04 2012-06-05 University Of Virginia Patent Foundation Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
CA2718983C (en) 2008-03-26 2015-12-08 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
JP2011528364A (ja) * 2008-07-16 2011-11-17 キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド アテローム性動脈硬化症の治療
WO2010103547A2 (en) 2009-03-13 2010-09-16 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
WO2011005871A1 (en) * 2009-07-07 2011-01-13 Pgxhealth, Llc Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine a2b antagonists
JP5843778B2 (ja) 2009-11-09 2016-01-13 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物、その調製およびその使用
JP5827998B2 (ja) 2010-09-13 2015-12-02 アドヴィナス・セラピューティックス・リミテッド Ａ２ｂアデノシン受容体アンタゴニストのプロドラッグとしてのプリン化合物、これらの方法および薬剤の適用
EP2465859A1 (en) * 2010-12-08 2012-06-20 Life & Brain GmbH 8-Triazolylxanthine derivatives, processes for their production and their use as adenosine receptor antagonists
CN102532137B (zh) * 2011-12-05 2014-12-10 辽宁医学院 8-吡唑取代黄嘌呤类a2b腺苷受体拮抗剂及其合成方法和应用
US11370792B2 (en) 2015-12-14 2022-06-28 Raze Therapeutics, Inc. Caffeine inhibitors of MTHFD2 and uses thereof
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
EP4126866A1 (en) * 2020-03-26 2023-02-08 Inspyr Therapeutics, Inc. 8-substituted diaryl xanthines as dual a2a-a2b antagonists
WO2022246392A1 (en) 2021-05-18 2022-11-24 Purnovate, Inc. Cyclic amide-containing pyridyl xanthines as a 2b antagonists
CN113262882B (zh) * 2021-07-21 2021-09-17 北京矿冶研究总院 阳离子捕收剂、制备方法及在磷矿反浮选中的应用
WO2024050825A1 (en) * 2022-09-09 2024-03-14 National Institute Of Biological Sciences, Beijing Compounds as mlkl inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
WO1999030715A1 (fr) * 1997-12-15 1999-06-24 Kyowa Hakko Kogyo Co., Ltd. Agents prophylactiques contre les troubles du sommeil et remedes aux troubles du sommeil
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6060481A (en) 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
EP1234576B1 (en) * 1999-10-29 2006-03-08 Kyowa Hakko Kogyo Co., Ltd. Pharmaceutical composition for eating disorders
MXPA02007761A (es) * 2000-02-17 2002-10-11 Cv Therapeutics Inc Metodo para identificar y utilizar antagonistas del receptor a2b de adenosina para mediar la proliferacion celular en mamiferos.
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
HU229504B1 (hu) * 2001-11-09 2014-01-28 Gilead Sciences A2B-adenozinreceptor-antagonisták
CA2443023A1 (en) * 2002-02-01 2003-08-07 King Pharmaceuticals Research And Development, Inc. 8-heteroaryl xanthine adenosine a2b receptor antagonists
US7034070B2 (en) * 2002-09-27 2006-04-25 Vincent Chuang Arylalkyl aminofunctional silanes for epoxy laminates
US7148229B2 (en) * 2003-02-19 2006-12-12 Hoffman-La Roche Inc. Sulfonamide substituted xanthine derivatives
EP2295434B1 (en) 2003-08-25 2015-09-30 Dogwood Pharmaceuticals, Inc. Substituted 8-heteroaryl xanthines
WO2006028810A2 (en) * 2004-09-01 2006-03-16 Cv Therapeutics, Inc. Method of wound healing using a2b adenosine receptor antagonists
CA2583986A1 (en) * 2004-10-15 2006-04-27 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists
WO2006091897A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
WO2006091936A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7618962B2 (en) * 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
US7601723B2 (en) * 2005-02-25 2009-10-13 Pgx Health, Llc Pyridyl substituted xanthines
CA2612344A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
RU2457842C2 (ru) * 2006-03-17 2012-08-10 Гайлид Пало Альто, Инк. Способ предотвращения и лечения болезни печени с использованием антагонистов рецептора аденозина a2b
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
CA2718983C (en) * 2008-03-26 2015-12-08 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist

Also Published As

Publication number Publication date
CN101851238B (zh) 2012-07-18
CN101851238A (zh) 2010-10-06
AU2004268964A1 (en) 2005-03-10
IL173723A0 (en) 2006-07-05
RU2357969C2 (ru) 2009-06-10
KR101222364B1 (ko) 2013-01-15
BRPI0413922B1 (pt) 2018-08-28
US7732455B2 (en) 2010-06-08
US20080200456A1 (en) 2008-08-21
PL1658291T3 (pl) 2014-03-31
US7342006B2 (en) 2008-03-11
PT1658291E (pt) 2013-10-21
BRPI0413922A (pt) 2006-10-24
CN1894250B (zh) 2010-06-09
EP1658291A2 (en) 2006-05-24
RU2006109474A (ru) 2007-10-10
ES2557310T3 (es) 2016-01-25
JP4769721B2 (ja) 2011-09-07
CA2536553C (en) 2013-01-29
CA2536553A1 (en) 2005-03-10
DK1658291T3 (da) 2013-10-28
AR045499A1 (es) 2005-11-02
JP2007503443A (ja) 2007-02-22
AU2004268964B2 (en) 2010-03-11
HK1096397A1 (en) 2007-06-01
ZA200602333B (en) 2007-04-25
EP1658291B1 (en) 2013-10-02
US20050065341A1 (en) 2005-03-24
WO2005021548A2 (en) 2005-03-10
KR20060132549A (ko) 2006-12-21
IL173723A (en) 2015-01-29
EP2295434A2 (en) 2011-03-16
US20100273780A1 (en) 2010-10-28
HK1148518A1 (en) 2011-09-09
WO2005021548A3 (en) 2005-06-30
NZ545715A (en) 2009-02-28
ES2440467T3 (es) 2014-01-29
EP2295434B1 (en) 2015-09-30
CN1894250A (zh) 2007-01-10
DK2295434T3 (en) 2015-12-14
EP2295434A3 (en) 2011-07-27
TWI362390B (en) 2012-04-21
TW200524931A (en) 2005-08-01

Similar Documents

Publication Publication Date Title
BRPI0413922B8 (pt) xantinas de 8-heteroarila substituída
WO2006091898A3 (en) Pyrazolyl substituted xanthines
WO2000073307A8 (en) Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors
ATE461932T1 (de) Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
GT200900187A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso los mismos
EA200900010A1 (ru) Замещенные 8-[6-амино-3-пиридил]ксантины
ECSP077236A (es) Moduladores del receptor de progesterona que comprenden los derivados del pirrol-oxindol y los usos de los mismos
MXPA06014798A (es) Antagonistas del receptor de hormona para liberar gonadotropina.
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10
CO6290760A2 (es) Derivados de alcoholes de 1 fenil-2-piridinilalquilo como inbidores de la fosfodiesterasa
MXPA03008967A (es) Antagonistas receptores de 8-heteroarilo xantina adenosina a-2b.
IL188725A0 (en) Pyrazine derivatives useful as adenosine receptor antagonists
UY29870A1 (es) Derivados de ftalazinona
AR058827A1 (es) Composiciones azeotropicas que comprenden 2,3,3,3-tetra-fluoropropeno y fluoruro de hidrogeno y sus usos
GT200200266A (es) Uso de ureas de benzotiazoles
SV2001000004A (es) Difenil ureas w-carboxyaril sustituidas, composición farmacéutica que las comprende y su uso como inhibidores de raf quinasa
GT200500008A (es) Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la sintesis de los mismos
GT200500375A (es) Derivados de piperidina y su uso como agentes antiinflamatorios
BR0215392A (pt) Composições farmacêuticas compreendendo um inibidor de fosfodiesterase multifuncional e um inibidor de absorção de adenosina, bem como uso das mesmas
BRPI0813218A2 (pt) Composto, composição farmacêutica que o contém como princípio ativo e uso do composto.
ATE365740T1 (de) Substituierte pyrazolopyrimidine
MX2010006645A (es) Esteres del acido 4-{3-[6-amino-9-(3,4-dihidroxi-tetrahidro-furan- 2-il)-9h-purin-2-il]-prop-2-inil}-piperidin-1-carboxilico sustituidos como agonistas del r a2a.
WO2008011007A3 (en) Selective antagonists of a2a adenosine receptors
DK1622908T3 (da) Xanthin-derivater som A2B adenosin-receptor-antagonister
WO2005040155A8 (en) Pyrimidin-2-amine derivates and their use as a2b adenosine receptor antagonists

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: PGX HEALTH, LLC (US)

Free format text: TRANSFERIDO DE: ADENOSINE THERAPEUTICS, LLC

B25D Requested change of name of applicant approved

Owner name: TROVIS PHARMACEUTICALS LLC (US)

Free format text: NOME ALTERADO DE: PGX HEALTH, LLC

B25A Requested transfer of rights approved

Owner name: TROVIS PHARMACEUTICALS HOLDINGS, INC. (US)

B25A Requested transfer of rights approved

Owner name: CLINICAL DATA, INC. (US)

B25A Requested transfer of rights approved

Owner name: DOGWOOD PHARMACEUTICALS, INC. (US)

B25A Requested transfer of rights approved

Owner name: FOREST LABORATORIES HOLDINGS LIMITED (BM)

B25A Requested transfer of rights approved

Owner name: DOGWOOD PHARMACEUTICALS, INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/08/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/08/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: ALLERGAN SALES, LLC (US)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2788 DE 11-06-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.